Assenagon Asset Management S.A. Raises Stake in Henry Schein, Inc. $HSIC

Assenagon Asset Management S.A. lifted its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 212.8% during the fourth quarter, HoldingsChannel reports. The firm owned 67,181 shares of the company’s stock after purchasing an additional 45,701 shares during the period. Assenagon Asset Management S.A.’s holdings in Henry Schein were worth $5,078,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in HSIC. MAI Capital Management raised its position in Henry Schein by 7.5% during the third quarter. MAI Capital Management now owns 2,061 shares of the company’s stock valued at $137,000 after acquiring an additional 144 shares in the last quarter. CW Advisors LLC grew its position in Henry Schein by 2.8% in the second quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock worth $432,000 after acquiring an additional 163 shares in the last quarter. Truist Financial Corp increased its stake in shares of Henry Schein by 3.3% during the 3rd quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock worth $368,000 after purchasing an additional 175 shares during the last quarter. Claret Asset Management Corp increased its stake in shares of Henry Schein by 6.3% during the 2nd quarter. Claret Asset Management Corp now owns 3,173 shares of the company’s stock worth $232,000 after purchasing an additional 187 shares during the last quarter. Finally, Jain Global LLC raised its holdings in shares of Henry Schein by 2.0% during the 3rd quarter. Jain Global LLC now owns 10,662 shares of the company’s stock valued at $708,000 after purchasing an additional 207 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Insider Buying and Selling

In other Henry Schein news, CEO Stanley M. Bergman sold 43,812 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $81.31, for a total value of $3,562,353.72. Following the completion of the transaction, the chief executive officer owned 383,803 shares of the company’s stock, valued at $31,207,021.93. This represents a 10.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kurt P. Kuehn sold 2,844 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total value of $224,562.24. Following the completion of the sale, the director owned 15,420 shares of the company’s stock, valued at $1,217,563.20. This represents a 15.57% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 105,911 shares of company stock worth $8,574,982. 1.08% of the stock is currently owned by corporate insiders.

Henry Schein Stock Performance

HSIC opened at $72.10 on Friday. The firm has a market capitalization of $8.27 billion, a P/E ratio of 22.05, a price-to-earnings-growth ratio of 2.13 and a beta of 0.88. The stock’s 50 day moving average price is $77.37 and its two-hundred day moving average price is $73.22. The company has a quick ratio of 0.76, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. Henry Schein, Inc. has a 12-month low of $60.56 and a 12-month high of $89.29.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.04. The business had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. Henry Schein’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the company posted $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, equities analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Leerink Partners restated a “market perform” rating on shares of Henry Schein in a report on Monday, March 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Mizuho increased their price objective on Henry Schein from $81.00 to $88.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Robert W. Baird set a $100.00 target price on Henry Schein and gave the stock an “outperform” rating in a report on Monday, February 23rd. Finally, Barrington Research set a $97.00 target price on Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Henry Schein currently has a consensus rating of “Hold” and an average target price of $85.58.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.